Summary Judgment Granted Upholding The Validity Of Formulation Patent Protecting ...

RELISTOR® Injection Protected from Generic Competition Until 2024 LAVAL, Quebec, May 2, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the"Company") today announced that the U.S. District Court for the District of New Jersey has granted a motion for partial summary judgment of validity of a formulation patent for RELISTOR® (methylnaltrexone bromide) Injection. The ruling prevents generic...This story is related to the following:Pharmaceuticals

Source: Industrial Newsroom - Health, Medical and Dental Supplies - May 3, 2018 Category: Medical Devices Source Type: news